Annual review of pharmacology and toxicology最新文献_第9页

Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health. 长链欧米茄-3 多不饱和脂肪酸对心血管健康的利弊。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-090208

Ivana Djuricic, Philip C Calder

引用次数: 6

An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. 一天一片阿司匹林:新的药理发展和癌症化学预防。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-052020-023107

David G Menter, Robert S Bresalier

{"title":"An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention.","authors":"David G Menter, Robert S Bresalier","doi":"10.1146/annurev-pharmtox-052020-023107","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052020-023107","url":null,"abstract":"Chemoprevention refers to the use of natural or synthetic agents to reverse, suppress, or prevent the progression or recurrence of cancer. A large body of preclinical and clinical data suggest the ability of aspirin to prevent precursor lesions and cancers, but much of the clinical data are inferential and based on descriptive epidemiology, case control, and cohort studies or studies designed to answer other questions (e.g., cardiovascular mortality). Multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers but may also cause other effects depending on the tissue or disease and organ site in question. The best-known biological targets of aspirin are cyclooxygenases, which drive a wide variety of functions, including hemostasis, inflammation, and immune modulation. Newly recognized molecular and cellular interactions suggest additional modifiable functional targets, and the existence of consensus molecular cancer subtypes suggests that aspirin may have differential effects based on tumor heterogeneity. This review focuses on new pharmacological developments and innovations in biopharmacology that clarify the potential role of aspirin in cancer chemoprevention.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"165-186"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10572248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Pharmacogenetics of Antiplatelet Therapy. 抗血小板疗法的药物遗传学。

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 Epub Date: 2022-01-08 DOI: 10.1146/annurev-pharmtox-051921-092701

Matteo Castrichini, Jasmine A Luzum, Naveen Pereira

{"title":"Pharmacogenetics of Antiplatelet Therapy.","authors":"Matteo Castrichini, Jasmine A Luzum, Naveen Pereira","doi":"10.1146/annurev-pharmtox-051921-092701","DOIUrl":"10.1146/annurev-pharmtox-051921-092701","url":null,"abstract":"Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of CYP2C19 genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"211-229"},"PeriodicalIF":11.2,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10606443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Delightful Trip Along the Pathway of Cannabinoid and Endocannabinoid Chemistry and Pharmacology. 沿着大麻素和内源性大麻素化学和药理学途径的愉快旅行。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-083709

Raphael Mechoulam

引用次数: 5

Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 超越勃起功能障碍:cgmp特异性磷酸二酯酶5抑制剂治疗其他临床疾病。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-040122-034745

Arun Samidurai, Lei Xi, Anindita Das, Rakesh C Kukreja

{"title":"Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.","authors":"Arun Samidurai, Lei Xi, Anindita Das, Rakesh C Kukreja","doi":"10.1146/annurev-pharmtox-040122-034745","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-040122-034745","url":null,"abstract":"Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide phosphodiesterase (PDE) family that specifically targets cGMP generated by nitric oxide-driven activation of the soluble guanylyl cyclase. PDE5 inhibitors, including sildenafil and tadalafil, are widely used for the treatment of erectile dysfunction, pulmonary arterial hypertension, and certain urological disorders. Preclinical studies have shown promising effects of PDE5 inhibitors in the treatment of myocardial infarction, cardiac hypertrophy, heart failure, cancer and anticancer-drug-associated cardiotoxicity, diabetes, Duchenne muscular dystrophy, Alzheimer's disease, and other aging-related conditions. Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular, anticancer, and neurological benefits. In this review, we provide an overview of the current state of knowledge on PDE5 inhibitors and their potential therapeutic indications for various clinical disorders beyond erectile dysfunction.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"585-615"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9792553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

CaMKII as a Therapeutic Target in Cardiovascular Disease. 作为心血管疾病治疗靶点的 CaMKII。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 Epub Date: 2022-08-16 DOI: 10.1146/annurev-pharmtox-051421-111814

Oscar E Reyes Gaido, Lubika J Nkashama, Kate L Schole, Qinchuan Wang, Priya Umapathi, Olurotimi O Mesubi, Klitos Konstantinidis, Elizabeth D Luczak, Mark E Anderson

{"title":"CaMKII as a Therapeutic Target in Cardiovascular Disease.","authors":"Oscar E Reyes Gaido, Lubika J Nkashama, Kate L Schole, Qinchuan Wang, Priya Umapathi, Olurotimi O Mesubi, Klitos Konstantinidis, Elizabeth D Luczak, Mark E Anderson","doi":"10.1146/annurev-pharmtox-051421-111814","DOIUrl":"10.1146/annurev-pharmtox-051421-111814","url":null,"abstract":"CaMKII (the multifunctional Ca2+ and calmodulin-dependent protein kinase II) is a highly validated signal for promoting a variety of common diseases, particularly in the cardiovascular system. Despite substantial amounts of convincing preclinical data, CaMKII inhibitors have yet to emerge in clinical practice. Therapeutic inhibition is challenged by the diversity of CaMKII isoforms and splice variants and by physiological CaMKII activity that contributes to learning and memory. Thus, uncoupling the harmful and beneficial aspects of CaMKII will be paramount to developing effective therapies. In the last decade, several targeting strategies have emerged, including small molecules, peptides, and nucleotides, which hold promise in discriminating pathological from physiological CaMKII activity. Here we review the cellular and molecular biology of CaMKII, discuss its role in physiological and pathological signaling, and consider new findings and approaches for developing CaMKII therapeutics.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"249-272"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9120748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem. 神经性疼痛：机理、性别差异和解决全球性问题的潜在疗法。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051421-112259

Shahrzad Ghazisaeidi, Milind M Muley, Michael W Salter

{"title":"Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem.","authors":"Shahrzad Ghazisaeidi, Milind M Muley, Michael W Salter","doi":"10.1146/annurev-pharmtox-051421-112259","DOIUrl":"10.1146/annurev-pharmtox-051421-112259","url":null,"abstract":"The study of chronic pain continues to generate ever-increasing numbers of publications, but safe and efficacious treatments for chronic pain remain elusive. Recognition of sex-specific mechanisms underlying chronic pain has resulted in a surge of studies that include both sexes. A predominant focus has been on identifying sex differences, yet many newly identified cellular mechanisms and alterations in gene expression are conserved between the sexes. Here we review sex differences and similarities in cellular and molecular signals that drive the generation and resolution of neuropathic pain. The mix of differences and similarities reflects degeneracy in peripheral and central signaling processes by which neurons, immune cells, and glia codependently drive pain hypersensitivity. Recent findings identifying critical signaling nodes foreshadow the development of rationally designed, broadly applicable analgesic strategies. However, the paucity of effective, safe pain treatments compels targeted therapies as well to increase therapeutic options that help reduce the global burden of suffering.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"565-583"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9126126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

KCNQ Potassium Channels as Targets of Botanical Folk Medicines. 作为民间植物药靶点的 KCNQ 钾通道

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-13 DOI: 10.1146/annurev-pharmtox-052120-104249

Kaitlyn E Redford, Geoffrey W Abbott

{"title":"KCNQ Potassium Channels as Targets of Botanical Folk Medicines.","authors":"Kaitlyn E Redford, Geoffrey W Abbott","doi":"10.1146/annurev-pharmtox-052120-104249","DOIUrl":"10.1146/annurev-pharmtox-052120-104249","url":null,"abstract":"Since prehistory, human species have depended on plants for both food and medicine. Even in countries with ready access to modern medicines, alternative treatments are still highly regarded and commonly used. Unlike modern pharmaceuticals, many botanical medicines are in widespread use despite a lack of safety and efficacy data derived from controlled clinical trials and often unclear mechanisms of action. Contributing to this are the complex and undefined composition and likely multifactorial mechanisms of action and multiple targets of many botanical medicines. Here, we review the newfound importance of the ubiquitous KCNQ subfamily of voltage-gated potassium channels as targets for botanical medicines, including basil, capers, cilantro, lavender, fennel, chamomile, ginger, and Camellia, Sophora, and Mallotus species. We discuss the implications for the traditional use of these plants for disorders such as seizures, hypertension, and diabetes and the molecular mechanisms of plant secondary metabolite effects on KCNQ channels.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"62 ","pages":"447-464"},"PeriodicalIF":11.2,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809153/pdf/nihms-1857008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10491528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes? 中枢神经系统对葡萄糖稳态的控制：2 型糖尿病的治疗目标？

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2022-01-06 DOI: 10.1146/annurev-pharmtox-052220-010446

Zaman Mirzadeh, Chelsea L Faber, Michael W Schwartz

引用次数: 0

Pharmacology of TRPC Channels and Its Potential in Cardiovascular and Metabolic Medicine. TRPC通道的药理作用及其在心血管和代谢医学中的潜力。

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2022-01-06 DOI: 10.1146/annurev-pharmtox-030121-122314

Robin S Bon, David J Wright, David J Beech, Piruthivi Sukumar

引用次数: 10